Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 3
2023 2
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean vap study investigators[Corporate Author] (2 results)?
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.
Alexander JL, Kennedy NA, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, Liu Z, Nice R, Bewshea C, D'Mello A, Constable L, Jones GR, Balarajah S, Fiorentino F, Sebastian S, Irving PM, Hicks LC, Williams HRT, Kent AJ, Linger R, Parkes M, Kok K, Patel KV, Teare JP, Altmann DM, Boyton RJ, Goodhand JR, Hart AL, Lees CW, Ahmad T, Powell N; VIP study investigators. Alexander JL, et al. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):342-352. doi: 10.1016/S2468-1253(22)00005-X. Epub 2022 Feb 4. Lancet Gastroenterol Hepatol. 2022. PMID: 35123676 Free PMC article.
Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine.
Liu Z, Alexander JL, Lin KW; VIP Study Investigators; Ahmad T, Pollock KM, Powell N. Liu Z, et al. Gastroenterology. 2023 Feb;164(2):300-303.e3. doi: 10.1053/j.gastro.2022.10.010. Epub 2022 Oct 19. Gastroenterology. 2023. PMID: 36270334 Free PMC article. No abstract available.
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.
Liu Z, Alexander JL, Le K, Zhou X, Ibraheim H, Anandabaskaran S, Saifuddin A, Lin KW, McFarlane LR, Constable L, Seoane RC, Anand N, Bewshea C, Nice R, D'Mello A, Jones GR, Balarajah S, Fiorentino F, Sebastian S, Irving PM, Hicks LC, Williams HR, Kent AJ, Linger R, Parkes M, Kok K, Patel KV, Teare JP, Altmann DM, Boyton RJ, Hart AL, Lees CW, Goodhand JR, Kennedy NA, Pollock KM, Ahmad T, Powell N; VIP study investigators. Liu Z, et al. EClinicalMedicine. 2023 Oct 5;64:102249. doi: 10.1016/j.eclinm.2023.102249. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37842172 Free PMC article.
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
Alexander JL, Liu Z, Muñoz Sandoval D, Reynolds C, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, Anand N, Nice R, Bewshea C, D'Mello A, Constable L, Jones GR, Balarajah S, Fiorentino F, Sebastian S, Irving PM, Hicks LC, Williams HRT, Kent AJ, Linger R, Parkes M, Kok K, Patel KV, Teare JP, Altmann DM, Goodhand JR, Hart AL, Lees CW, Boyton RJ, Kennedy NA, Ahmad T, Powell N; VIP study investigators. Alexander JL, et al. Lancet Gastroenterol Hepatol. 2022 Nov;7(11):1005-1015. doi: 10.1016/S2468-1253(22)00274-6. Epub 2022 Sep 9. Lancet Gastroenterol Hepatol. 2022. PMID: 36088954 Free PMC article.
COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies.
Bhella S, Wilkin AM, Hueniken K, Vijenthira A, Sebag M, Wang P, Hicks LK, Hay AE, Assouline S, Fraser G, Balitsky A, Mangel J, Owen C, Reiman A, Sehn L, Sutherland H, Zhang T, Arnold C, Leite T, McCarthy E, Cooper C, Langlois MA, Arianne Buchan C; VIP Study Investigators. Bhella S, et al. Vaccine. 2024 Oct 24;42(24):126074. doi: 10.1016/j.vaccine.2024.06.041. Epub 2024 Jun 28. Vaccine. 2024. PMID: 38944577 Free article.
Impact of C-reactive protein point-of-care testing on antibiotic prescriptions for children and adults with suspected respiratory tract infections in primary care: a French patient-level randomized controlled superiority trial.
Jung C, Levy C, Béchet S, Aegerter P, Cohen R, Touitou R; VIP Study Investigators. Jung C, et al. Clin Microbiol Infect. 2024 Dec;30(12):1553-1558. doi: 10.1016/j.cmi.2024.07.014. Epub 2024 Jul 26. Clin Microbiol Infect. 2024. PMID: 39067513 Free article. Clinical Trial.
Incremental immunogenicity of multiple doses of SARS-CoV-2 vaccination in patients with haematological malignancies.
Vijenthira A, Bhella S, Hueniken K, Wilkin AM, Sebag M, Wang P, Hicks LK, Hay AE, Assouline S, Balitsky A, Fraser G, Mangel J, Owen C, Reiman A, Sehn L, Sutherland H, Arnold C, Leite T, McCarthy E, Crawley A, Cooper C, Langlois MA, Buchan CA; VIP Study Investigators. Vijenthira A, et al. Br J Haematol. 2025 Oct;207(4):1632-1637. doi: 10.1111/bjh.70054. Epub 2025 Jul 30. Br J Haematol. 2025. PMID: 41070659 Free PMC article. No abstract available.
Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular Therapy.
Buchan CA, Agbayani G, Hueniken K, Vijenthira A, Sebag M, Wang P, Hicks LK, Hay AE, Assouline S, Fraser G, Balitsky A, Mangel J, Owen C, Reiman A, Sehn L, Sutherland H, Zhang T, Arnold C, Wilkin AM, Leite T, McCarthy E, Crawley AM, Langlois MA, Bredeson C, Kekre N, Allan D, Cooper C, Bhella S; VIP Study Investigators. Buchan CA, et al. Transplant Cell Ther. 2025 Nov 8:S2666-6367(25)01551-9. doi: 10.1016/j.jtct.2025.10.037. Online ahead of print. Transplant Cell Ther. 2025. PMID: 41213500